ProfileGDS5678 / 1453824_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 62% 62% 60% 62% 65% 66% 62% 62% 62% 62% 62% 62% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7265962
GSM967853U87-EV human glioblastoma xenograft - Control 23.7188862
GSM967854U87-EV human glioblastoma xenograft - Control 33.7156762
GSM967855U87-EV human glioblastoma xenograft - Control 43.5607960
GSM967856U87-EV human glioblastoma xenograft - Control 53.6642162
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9734865
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0580266
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7209562
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7200162
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7073162
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7153362
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6832462
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.723362
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7242662